PFCS
SCPH

Pale Fire Capital SE’s scPharmaceuticals SCPH Stock Holding History

Pale Fire Capital SE’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-57,128
Closed -$218K – 68
2025
Q2 		$218K Buy
+57,128
New +$177K 0.02% 44

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $239B AUM 42.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Pale Fire Capital SE's SCPH Position: Q3 2025 in Review

Pale Fire Capital SE sold out of scPharmaceuticals (SCPH) in Q3 2025, closing a stake of 57,128 shares — an estimated $218K sold.

Pale Fire Capital SE first reported a position in SCPH in Q2 2025 and held it in 1 quarter. The position peaked at $218K in Q2 2025. 110 funds tracked by Wall St. Rank hold SCPH as of Q3 2025.

  • Pale Fire Capital SE reported no remaining scPharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Pale Fire Capital SE sold 57,128 scPharmaceuticals shares in Q3 2025, an estimated $218K.
  • Pale Fire Capital SE first reported a position in scPharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Pale Fire Capital SE's scPharmaceuticals position peaked at $218K in Q2 2025.
  • 110 funds tracked by Wall St. Rank held scPharmaceuticals as of Q3 2025.

Based on Pale Fire Capital SE's 13F filing for Q3 2025, filed 13 Nov 2025.